PD-1/PD-L1 inhibitors have shown remarkable efficacy in treating recurrent/metastatic cervical cancer [17, 18], and the FDA has approved pembrolizumab and nivolumab for treating recurrent/metastatic cervical cancer. This evidence concerns the gene CD274 and cervical cancer.